Robert J. Fontana has conducted research and consulted for Bristol-Myers Squibb. Eric A. Hughes, Dessislava Dimitrova, and Marc Bifano are employees of Bristol-Myers Squibb. Robert Hindes was formerly employed by Bristol-Myers Squibb and is currently employed by Gilead Sciences.
Article first published online: 27 AUG 2012
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 18, Issue 9, pages 1053–1059, September 2012
How to Cite
Fontana, R. J., Hughes, E. A., Appelman, H., Hindes, R., Dimitrova, D. and Bifano, M. (2012), Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl, 18: 1053–1059. doi: 10.1002/lt.23482
This work was supported in part by the National Institutes of Health through its support of the Michigan Institute for Clinical and Health Research (grant UL1RR024986). The investigational agent, daclatasvir, was supplied by Bristol-Myers Squibb.
- Issue published online: 27 AUG 2012
- Article first published online: 27 AUG 2012
- Accepted manuscript online: 18 JUN 2012 05:05AM EST
- Manuscript Accepted: 1 MAY 2012
- Manuscript Received: 21 MAR 2012
A recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) can lead to accelerated allograft injury and fibrosis. The aim of this article is to report the first ever use of daclatasvir (DCV; also known as BMS-790052), a potent orally administered nonstructural 5A replication complex inhibitor, in combination with peginterferon α (PEG-IFNα) and ribavirin in an LT recipient. A 49-year-old female developed a severe recurrent HCV genotype 1b infection 4 months after transplantation with severe cholestasis on biopsy, an HCV RNA level of 10,000,000 IU/mL, an alkaline phosphatase level of 1525 IU/mL, and a total bilirubin level of 8.4 mg/dL. Despite partial virological suppression with PEG-IFNα and ribavirin, progressive allograft failure ensued and culminated in retransplantation at 9 months. Three months after the second transplant, DCV (20 mg/day), PEG-IFNα2a (180 μg/week), and ribavirin (800 mg/day) were prescribed for early recurrent cholestatic HCV. Serum HCV RNA became undetectable at week 3 of treatment and remained undetectable during 24 weeks of triple therapy and during the posttreatment follow-up. DCV was well tolerated, and the trough drug levels were within the targeted range throughout the treatment. The cyclosporine trough levels were also stable during and after therapy. In conclusion, the lack of anticipated drug-drug interactions between DCV and calcineurin inhibitors and the potent antiviral efficacy of DCV make this agent (in combination with PEG-IFN and ribavirin) an attractive antiviral regimen worthy of further study in LT recipients with recurrent HCV. Liver Transpl, 2012. © 2012 AASLD.